(Boursier.com) — inventive a biopharmaceutical company specializing in the clinical development of orally administered small molecules for the treatment of nonalcoholic steatohepatitis (NASH) and other diseases with unmet medical need, today announces the co-optation of Dr. Lucy Lu in as director on its Board of Directors, from November 9, 2022, in place of Sofinnova Partners.
The appointment of Dr. Lucy Lu will be submitted to the shareholders for ratification at the next Inventiva General Meeting.
Dr. Lucy Lu has been the Sofinnova Partners representative on the Inventiva Board of Directors since January 4, 2020. Dr. Lu has a broad experience of more than 20 years in the biotechnology and healthcare sectors in as an investment banker, financial analyst and managing director. Dr. Lu is Chief Operating Officer at Innovative Cellular Therapeutics and was previously President and CEO of Avenue Therapeutics. Dr. Lu has also worked as a biotechnology financial analyst for Citigroup Inc. and holds an MD from New York University School of Medicine.
Frédéric Cren, Chairman and CEO and co-founder of Inventiva, commented: “We are very pleased to appoint Dr. Lu as Director of the Board of Inventiva. Dr. Lu has served on the Board for almost three years, and his global knowledge of the sector is a great asset for the Company, in particular with the development of lanifibranor and the signing of a first licensing agreement for the development and commercialization of lanifibranor in Greater China. of Directors, I would like to thank Dr. Lu for his continued participation on the Board, and I also thank Sofinnova Partners for their contribution to Inventiva’s success over the past three years.”
©2022 Boursier.com